Charles River Laboratories International (NYSE:CRL) Price Target Raised to $387.00

Posted by George Bondi on Nov 5th, 2026

Charles River Laboratories International (NYSE:CRL – Get Free Report) had its target price lifted by investment analysts at UBS Group from $357.00 to $387.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the medical research company’s stock. UBS Group‘s price objective would suggest a potential upside of 23.82% from the company’s current price.

Other equities research analysts have also recently issued reports about the stock. Piper Sandler set a $300.00 price target on shares of Charles River Laboratories International in a research note on Monday, August 10th. Jefferies Financial Group boosted their price objective on shares of Charles River Laboratories International from $305.00 to $340.00 and gave the company a “buy” rating in a research report on Monday, September 28th. Evercore set a $330.00 price objective on shares of Charles River Laboratories International in a research note on Friday, September 25th. Argus set a $330.00 target price on shares of Charles River Laboratories International in a research report on Thursday, September 17th. Finally, CLSA cut shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 target price for the company. in a research note on Monday, July 20th. Thirteen research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $308.17.

Check Out Our Latest Analysis on Charles River Laboratories International

Charles River Laboratories International Price Performance

Charles River Laboratories International stock traded down $13.75 during mid-day trading on Thursday, hitting $312.54. 1,661,444 shares of the company were exchanged, compared to its average volume of 966,386. Charles River Laboratories International has a 12-month low of $146.20 and a 12-month high of $379.63. The company has a market capitalization of $14.92 billion, a P/E ratio of -64.44, a PEG ratio of 3.29 and a beta of 1.36. The business’s 50 day simple moving average is $304.55 and its two-hundred day simple moving average is $224.12. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04.

Charles River Laboratories International (NYSE:CRL – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The medical research company reported $3.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.97 by $0.12. The business had revenue of $982.73 million for the quarter, compared to the consensus estimate of $960.36 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%. The business’s revenue was down 2.2% on a year-over-year basis. During the same period in the prior year, the business earned $2.43 earnings per share. Analysts forecast that Charles River Laboratories International will post 11.38 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Nancy C. Andrews sold 573 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $285.24, for a total transaction of $163,442.52. Following the transaction, the director directly owned 1,438 shares in the company, valued at $410,175.12. This represents a 28.49% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Birgit Girshick sold 6,500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $279.90, for a total transaction of $1,819,350.00. Following the completion of the sale, the chief executive officer directly owned 36,013 shares in the company, valued at $10,080,038.70. This represents a 15.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 102,299 shares of company stock valued at $31,050,863 in the last quarter. Corporate insiders own 1.30% of the company’s stock.

Hedge Funds Weigh In On Charles River Laboratories International

A number of hedge funds have recently made changes to their positions in CRL. Maryland State Retirement & Pension System grew its stake in shares of Charles River Laboratories International by 440.4% during the 3rd quarter. Maryland State Retirement & Pension System now owns 14,395 shares of the medical research company’s stock valued at $4,247,000 after buying an additional 11,731 shares during the period. Lisanti Capital Growth LLC purchased a new position in shares of Charles River Laboratories International in the 3rd quarter worth $1,831,000. Lido Advisors LLC purchased a new position in shares of Charles River Laboratories International in the 3rd quarter worth $1,205,000. New York Life Investment Management LLC boosted its holdings in Charles River Laboratories International by 371.3% in the third quarter. New York Life Investment Management LLC now owns 61,506 shares of the medical research company’s stock valued at $18,145,000 after acquiring an additional 48,455 shares during the last quarter. Finally, AlphaCore Capital LLC boosted its holdings in Charles River Laboratories International by 222.4% in the third quarter. AlphaCore Capital LLC now owns 5,184 shares of the medical research company’s stock valued at $1,529,000 after acquiring an additional 3,576 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Key Stories Impacting Charles River Laboratories International

Here are the key news stories impacting Charles River Laboratories International this week:

Positive Sentiment: Charles River reported Q3 adjusted earnings of $3.09 per share and revenue of $982.7 million, topping analyst estimates. Margin expansion helped earnings, and the company raised its 2026 outlook. Charles River Q3 Earnings & Revenues Top Estimates, Stock Rises
Positive Sentiment: Barclays raised its price target to $375 and maintained an Overweight rating; RBC lifted its target to $352 and kept an Outperform rating. The higher targets signal continued analyst optimism. Barclays stock recommendations Royal Bank of Canada stock recommendations
Neutral Sentiment: The market’s reaction appears cautious despite the earnings beat: revenue exceeded estimates but was down 2.2% from a year earlier, and coverage noted the shares fell despite the beat and raised outlook. CRL Q3 2026 deep dive
Negative Sentiment: Zacks Research downgraded CRL from Strong Buy to Hold, adding a more cautious analyst view. Zacks Research stock recommendations

Charles River Laboratories International Company Profile

(Get Free Report)

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.